Результаты поиска

Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: a scoping review.

INTRODUCTION: Some patients diagnosed with cancer use medical cannabis to self-manage undesirable symptoms, including nausea and pain. To improve patient safety and oncological care quality, the routes of administration for use of medical cannabis, patients' reasons, and prescribed indications must be better understood. METHODS: Based on the Joanna Briggs Institute guidelines, a scoping review was conducted to map the current evidence regarding the use of medical cannabis in oncological settings based on the experiences of patients diagnosed with cancer and their healthcare providers. A searc

Совпадение в полном тексте источника
… Taha T Meiri D Talhamy S Wollner M Peer A Bar-Sela G Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies Oncologist 2019 24 4 549 554 30670598 10.1634/theoncologist.2018-0383 PMC6459234 58. … Braun IM Wright A Peteet J Meyer FL Yuppa DP Bolcic-Jankovic D Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study J Clin Oncol 2018 36 19 1957 1962 29746226 10.1200/JCO.2017.76.1221 PMC6553839 134. …

Первый рецидив у пожилых людей с множественной миеломой: создание новых путей на неизведанных территориях.

Варианты лечения пожилых людей с повторной множественной миеломой ограничиваются токсичностью существующих методов лечения, уязвимостью, связанной со старением, которая может повысить риск нетерпимого отношения к лечению, и предпочтениями пациентов в отношении лечения, которое не наносит ущерба их функционированию или восприятию. В исследовании Туссеа и др. излагаются подходы к разработке испытаний, конкретно предназначенных для более уязвимых пожилых людей, и проводится работа в поле с режимом, представляющим большой интерес для пожилых людей, сталкивающихся с их первым рецидивом. Комментарий

Editorial: Understanding patient nutrition and cancer progression.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients. Ther Adv Med Oncol. (2019) 11:1758835919880084. doi: 10.1177/1758835919880084 12. Salas S, Cottet V, Dossus L, Fassier P, Ginhac J, Latino-Martel P, et al. …

Немногодействующий клеточный ассоциированный гематотоксичный с вторичным миэлофиброзом после Идекабтаген-Виклеукеля для множественной миеломы, полностью обработанный аутентичным гематопоэтическим сетком.

Panktopenia в сочетании с химериковой антигенной рецепторной клеткой T (CAR-T) называется иммунной гематопоиетической токсичностью (ICAHT), которая часто устойчива и противодействует поддержке. Мы сообщаем о случае 52-year-old Человек с множественной миеломой, который развил серьёзный ИКАХТ с вторичным миэлофиброзом (SMF) после введения идекабатагена-виклеукаля, который был полностью усовершенствован за счет аутологического гематопоиетического усиления стволовых клеток. В данном случае основное внимание уделяется СМФ как редким, но осторожным осложнениям CAR-T-терапии, что подчеркивает важност

Delayed Diagnosis of Cardiac Amyloidosis Masked by Chronic Coronary Artery Disease and Ischemic Cardiomyopathy: A Case Report of an Overlooked and Underdiagnosed Etiology.

Cardiac amyloidosis (CA) is an infiltrative disease of the heart characterized by the deposition of insoluble protein aggregates in the myocardium. There are two subtypes of CA, and they are named after the misfolded protein. Transthyretin cardiac amyloidosis (ATTR-CA) is caused by the accumulation of the tetrameric transthyretin protein produced in the liver, and light-chain cardiac amyloidosis (AL-CA) occurs due to circulating abnormal light-chain deposition. Disease manifestation can be very non-specific, and there can be overlap with other cardiac processes. This often leads to a delay in

Совпадение в полном тексте источника
… Early detection and appropriate therapy can help halt the progression of cardiac damage, but delayed diagnosis is frequent and may require multiple visits to different subspecialty physicians, including interventional cardiologists, electrophysiologists, neurologists, and hematology oncologists for an …

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma.

This cohort study examines the risk of skeletal-related events associated with the frequency of bisphosphonate treatment in patients with multiple myeloma.

Совпадение в полном тексте источника
… The findings of this cohort study agree with findings from randomized clinical trials showing that less frequent IV bisphosphonate administration frequency was associated with comparable recurrent SRE risk reductions as more frequent administration. 6 In clinical practice, there are many reasons why oncologists …

Hypocalcemia in cancer patients: An exploratory study.

IntroductionCalcium has several physiological functions and when it registers abnormal serum levels those functions may be impacted with potentially severe consequences. There is much research on hypercalcemia in cancer patients, but there are no recent studies on the prevalence of hypocalcemia in those patients. However, there has been an evolution in oncology, namely, new drugs that may directly or indirectly result in hypocalcemia. The primary aim was to explore the association of hypocalcemia with the diverse types of cancer. The secondary aim was to study the influence that hypocalcemia m

Factors influencing physical activity participation among people living with or beyond cancer: a systematic scoping review.

BackgroundIt has been posited that physical activity (PA) has the potential to improve health outcomes and the health-related quality of life of people living with or beyond cancer. Despite the well-documented health benefits of PA, there is a low level of PA among cancer patients. A systematic scoping review was conducted to investigate attitudes, perceptions, preferences and barriers vs. facilitators to cancer patients' PA participation.MethodsA systematic search was performed across four automated databases (PubMed, Embase, PsycINFO and Medline) in keeping with the PRISMA guideline. All can

Совпадение в полном тексте источника
… Persons to provide information and time to start Studies showed that oncologists were the most preferable source of information among patients across cancer types, followed by physiotherapists and nurses (Table 3 ). … Around 60–80% of mixed cancer patient participants in three different quantitative and qualitative studies preferred to receive PA information from oncologists [ 38 , 46 , 85 ]. Other preferable sources of PA information included family doctors and personal trainers. …

Prescription and use of psychoactive medications among cancer patients and associated factors in lower and upper middle-income countries: systematic review.

PURPOSE: To describe the prescription and use of psychoactive medications among cancer patients in low- and middle-income countries (LMICs) and explore the factors influencing their prescription and use. METHODS: This systematic review was conducted following the PRISMA guidelines. Six electronic databases were searched. We included observational studies that investigated the prescription and use of psychoactive medications among adult cancer patients in low- and middle-income countries (LMICs) according to the 2024 World Bank's classification. Eligible studies specifically focused on the use

Совпадение в полном тексте источника
… recruited from the oncology department of a university hospital in Beijing, China) Depressive disorders (25.9%): *Major depressive disorder (MDD): 12.6 *Dysthemia: 9.1 *Minor depressive disorder: 1.7 *Mood disorder: 2.4 Antidepressants (25.9%) NI Only 3.4% of depressed patients were recognized by their oncologists … from the oncology department of a university hospital in Beijing, China) | Depressive disorders (25.9%): *Major depressive disorder (MDD): 12.6 *Dysthemia: 9.1 *Minor depressive disorder: 1.7 *Mood disorder: 2.4 | Antidepressants (25.9%) | NI | Only 3.4% of depressed patients were recognized by their oncologists …

The effect of social care nurses on health related quality of life in patients with advanced cancer: A non-randomized, multicenter, controlled trial.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Furthermore, patients were recruited in hospitals where specialized oncology nurses, psycho-oncologists and social workers are routinely part of the team and get regularly involved over time, especially as the disease progresses. … A national survey of medical oncologists. Supportive Care in Cancer , 27 (4), 1375–1382. 5. van Oorschot, B. (2018). Krebs Im Endstadium: Überengagierte Versorgung am Lebensende. Dtsch Arztebl International , 115 (47), 16. 6. Hansen, D. G., Larsen, P. V., Holm, L. V., Rottmann, N., Bergholdt, S. …

A mixed methods evaluation of patient perspectives on the implementation of an electronic health record-integrated patient-reported symptom and needs monitoring program in cancer care.

BACKGROUND: As cancer centers have increased focus on patient-centered, evidenced-based care, implementing efficient programs that facilitate effective patient-clinician communication remains critical. We implemented an electronic health record-integrated patient-reported symptom and needs monitoring program ('cPRO' for cancer patient-reported outcomes). To aid evaluation of cPRO implementation, we asked patients receiving care in one of three geographical regions of an academic healthcare system about their experiences. METHODS: Using a sequential mixed-methods approach, we collected feedbac

Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Population Aging: A Challenge for Oncologists 1.1. Malignant Hemopathies: Diseases of Older Patients The median age of the population is increasing and, within 10 years, it is expected that 30% of the European population will be older than 60 years. … This represents a challenge for hemato-oncologists who will have to face the increased incidence of malignant hemopathies with a median age above 65 years [ 1 , 2 , 3 ]. Lymphomas are the most common hematological malignancies, accounting for 30% of these malignant hemopathies. …

Development of a Patient-Centered Preference Tool for Patients With Hematologic Malignancies: Protocol for a Mixed Methods Study.

BackgroundThe approval of novel therapies for patients diagnosed with hematologic malignancies have improved survival outcomes but increased the challenge of aligning chemotherapy choices with patient preferences. We previously developed paper versions of a discrete choice experiment (DCE) and a best-worst scaling (BWS) instrument to quantify the treatment outcome preferences of patients with hematologic malignancies to inform shared decision making.ObjectiveWe aim to develop an electronic health care tool (EHT) to guide clinical decision making that uses either a BWS or DCE instrument to capt

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.

PurposeCamrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. We aimed to assess the efficacy and safety of a novel combination of famitinib, camrelizumab, and nab-paclitaxel in advanced immunomodulatory TNBC.Patients and methodsThis open-label, single-arm, phase II study enrolled patients with previously untreated, advanced, immunomodulatory TNBC (CD8 IHC staining ≥1

A qualitative study on patients' and their support persons' preferences for receiving one longer consultation or two shorter consultations when being informed about allogeneic hematopoietic stem cell transplantation.

BackgroundAllogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment option for many patients with hematological disorders but it includes a significant risk of mortality and long-term morbidity. Many patients and their support persons feel overwhelmed when being informed about alloHSCT and may benefit from improvements in consultation style and timing.AimsTo explore, qualitatively, in a sample of hematological cancer patients and their support persons, their preferences for receiving one longer consultation or two shorter consultations when being

Совпадение в полном тексте источника
… Some transplant centres offer additional written information for their patients to consider at home after the consultation and provide the opportunity to contact the treatment team, which often involves psycho-oncologists, should patients or support persons have further questions. … TL, Chapman R, Harper FWK, Thompson H, Griggs JJ, Gonzalez R, Berry-Bobovski L, Tkatch R, Simon M, Shields A, Gadgeel S, Loutfi R, Ali H, Wollner I, Penner LA (2017) Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists …

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.

Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications-including bleeding and potential drug-drug interactions with chemotherapy-associated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagulants (DOACs) could partially overcome these issues, but until recently there were no large clinical trials assessing their efficacy and safety in cancer patients. This review summarizes clinical treatment guidelines, prior clinical and real-world evidence for anticoagulant choice, recent clinical tri

Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study.

BACKGROUND: People with haematological malignancies have different end-of-life care patterns from those with other cancers and are more likely to die in hospital. Little is known about patient and relative preferences at this time and whether these are achieved. AIM: To explore the experiences and reflections of bereaved relatives of patients with leukaemia, lymphoma or myeloma, and examine (1) preferred place of care and death; (2) perceptions of factors influencing attainment of preferences; and (3) changes that could promote achievement of preferences. DESIGN: Qualitative interview study

Совпадение в полном тексте источника
… Oncologist 2012; 17(12): 1574–1580. 12. Bennett MI, Ziegler L, Allsop M, et al. What determines duration of palliative care before death for patients with advanced disease? A retrospective cohort study of community and hospital palliative care provision in a large UK city. … A clinical review of communication training for haematologists and haemato-oncologists: a case of art versus science. Br J Haematol 2017; 178(1): 11–19. 64. Alonso-Babarro A, Astray-Mochales J, Dominguez-Berjon F, et al. …

Oral Mucositis Induced By Anticancer Therapies.

Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors

Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.

The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody-drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term cancer survivors, an increasing incidence of previously unrecognized treatment-related toxicities has emerged. Among these, cardiovascular adverse events represent some of the most prevalent and clinically significant complications observed in both conventional chemother

Совпадение в полном тексте источника
… The cardio-oncologist’s role extends beyond surveillance of therapy-related cardiotoxicity. … As such, cardio-oncology must be embedded within a multidisciplinary network, fostering continuous dialogue between oncologists and cardiologists through regular meetings and shared protocols. …